Calcium Folinate (Folinic Acid): The Active Folate That Bypasses DHFR — A Research-Backed Guide
⚡ 60-Second Summary
Calcium folinate — commonly known as folinic acid or by its pharmaceutical name leucovorin — is a metabolically active form of vitamin B9 (folate). Its key distinction from folic acid and even from methylfolate (5-MTHF) is that it is the 5-formyl form of tetrahydrofolate (5-formyl-THF), which enters the folate cycle without requiring dihydrofolate reductase (DHFR). This makes it uniquely valuable when DHFR is blocked (by methotrexate) or when there is a clinical need to bypass that enzymatic step.
Primary clinical use: Leucovorin rescue — administered after high-dose methotrexate in cancer chemotherapy to protect normal tissues. Also used to reduce MTX side effects in lower-dose RA treatment, and supplementally for people with severe MTHFR mutations or specific folate metabolism disorders.
Important distinction: Folinic acid is not the same as folic acid, and it is not the same as methylfolate (5-MTHF). It still requires conversion to 5-MTHF by the MTHFR enzyme before it can donate methyl groups. It is not first-line for general folate supplementation — for most people, methylfolate (5-MTHF) is more directly useful for methylation support.
What is calcium folinate (folinic acid)?
Folate (vitamin B9) is the generic term for a family of related compounds essential for one-carbon metabolism — the biochemical infrastructure for DNA synthesis, DNA methylation, amino acid interconversion, and neurotransmitter production. The body uses folate in the form of tetrahydrofolate (THF) and its derivatives.
Folinic acid is the common name for 5-formyltetrahydrofolate (5-formyl-THF). In pharmaceutical and clinical contexts, it is called leucovorin. As a supplement, it is most often sold as its calcium salt — calcium folinate. Key properties:
- It is already in the tetrahydro (reduced) form — it does not need to pass through dihydrofolate reductase (DHFR) to be metabolically active
- It enters the folate cycle as a precursor to 5,10-methenyl-THF and subsequently to 5-MTHF
- It still requires the MTHFR enzyme for the final conversion to 5-MTHF (the methyl-donating form) — so it is not a complete bypass of MTHFR, unlike methylfolate (5-MTHF) itself
- It is the form used clinically to rescue tissues from methotrexate toxicity because MTX specifically inhibits DHFR, and folinic acid bypasses that block
Evidence-based benefits and clinical uses
1. Methotrexate rescue therapy (leucovorin rescue) — established, high-evidence
This is the best-established use of folinic acid. High-dose methotrexate (HD-MTX), used in treatment of certain cancers (osteosarcoma, lymphoma, leukemia), would be fatally toxic without leucovorin rescue. Leucovorin is administered on a defined schedule after HD-MTX, bypassing the DHFR block to restore folate-dependent biosynthesis in normal tissues. Serum MTX levels are monitored to time leucovorin administration precisely — rescue is continued until MTX levels fall below a defined threshold. This is a well-established pharmacological protocol, not a supplement use.
2. Methotrexate side effect reduction in rheumatoid arthritis (and other inflammatory conditions)
Low-dose methotrexate (7.5–25 mg/week) is a cornerstone treatment for rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease. It commonly causes GI side effects, oral ulcers, fatigue, and occasional hepatotoxicity. Supplementing with folic acid or folinic acid significantly reduces these side effects. A 2013 Cochrane review confirmed that folate supplementation (folic acid 1–5 mg/day or folinic acid on the day after MTX) reduced MTX discontinuation rates and mucositis without reducing anti-inflammatory efficacy. Folinic acid is sometimes preferred for patients who experience breakthrough side effects on folic acid.
3. Folate supplementation in severe MTHFR variants or DHFR impairment
For people with rare, severe MTHFR enzyme deficiency (distinct from the common polymorphisms), folinic acid may be used supplementally because it partially bypasses the impaired MTHFR step — though methylfolate (5-MTHF) bypasses it more completely. Folinic acid may also be appropriate for individuals who cannot tolerate methylfolate (some report anxiety or activation symptoms with 5-MTHF) and who also do not convert folic acid well.
4. Neural tube defect prevention (as part of folate adequacy)
Like all folate forms, folinic acid supports the folate-dependent thymidylate synthesis and purine biosynthesis pathways essential for neural tube closure in early pregnancy. However, folic acid is the form studied in neural tube defect prevention RCTs (MRC Vitamin Study, 1991), and current guidelines recommend folic acid or 5-MTHF for periconceptional supplementation — not specifically folinic acid. Folinic acid can serve as a folate source when folic acid is contraindicated or ineffective.
Understanding the folate cycle: where folinic acid fits
The folate cycle involves several interconversions of THF derivatives. Here is a simplified pathway showing where each form enters:
- Folic acid → (requires DHFR step 1) → dihydrofolate (DHF) → (requires DHFR step 2) → tetrahydrofolate (THF) → enters folate cycle
- Folinic acid (5-formyl-THF) → enters folate cycle directly (no DHFR needed) → eventually converted to 5-MTHF by MTHFR
- Methylfolate (5-MTHF) → enters folate cycle at the end-point; directly donates methyl group via methionine synthase; bypasses both DHFR and MTHFR
Key implication: folinic acid cannot rescue the MTHFR-impaired step in the same way 5-MTHF can. For people with MTHFR C677T homozygous variants seeking methylation support, methylfolate (5-MTHF) remains the more targeted choice. Folinic acid is the appropriate choice specifically when DHFR is the blocked or rate-limiting step.
Folate supplement forms compared
| Form | Chemical name | DHFR needed? | MTHFR needed? | Best for |
|---|---|---|---|---|
| Folic acid | Pteroylmonoglutamic acid | Yes (2 steps) | Yes | General supplementation, pregnancy (proven NTD prevention); not suitable when DHFR is blocked |
| Calcium folinate (folinic acid) | 5-formyl-THF (leucovorin) | No | Yes (still needs MTHFR) | MTX rescue; MTX side effect reduction; DHFR-bypass situations; alternative when folic acid is contraindicated |
| Methylfolate (5-MTHF) | 5-methyltetrahydrofolate | No | No (bypasses completely) | MTHFR variant support; methylation cycle; active folate supplementation for MTHFR C677T; most direct active form for methylation |
| Food folate | Polyglutamate forms of THF | No (food folate is already reduced) | Yes | Dietary folate from leafy greens, legumes, liver; bioavailability ~50–80% vs 85–100% for synthetic forms |
How much folinic acid should you take?
Dosing varies dramatically by indication:
- Leucovorin rescue (HD-MTX chemotherapy): Individualized by oncology team based on MTX dose and serum levels — typically 10–100+ mg IV or oral, repeated doses until MTX clearance. This is strictly a medical protocol.
- MTX side effect reduction in RA (low-dose MTX): 5 mg oral folinic acid once weekly, typically 12–24 hours after MTX dose. Folic acid (1–5 mg/day) is often used instead and is typically first-line due to lower cost.
- Supplemental folate support (MTHFR or DHFR context): 200–800 mcg/day of calcium folinate is used in some clinical protocols; start low and titrate under clinician guidance
- General dietary folate equivalents: The RDA is 400 mcg DFE for adults, 600 mcg for pregnancy. Folinic acid can contribute to this; 1 mcg of folinic acid = approximately 1.7 mcg DFE
Folinic acid is not a first-line choice for general folate supplementation. For most adults and pregnant women without specific indications, folic acid or methylfolate (5-MTHF) are more appropriate and better studied for their respective uses.
Safety and side effects
Calcium folinate at supplemental doses (200–800 mcg/day) has a good safety profile, similar to other folate forms. Key considerations:
- High-dose folinic acid can mask B12 deficiency anemia — the same concern as with folic acid. Elevated folate corrects megaloblastic anemia while allowing B12-deficiency neuropathy to progress. Always assess B12 status alongside folate supplementation.
- No established UL for folinic acid specifically; the 1,000 mcg UL for folic acid (synthetic folate) is based on masking B12 deficiency — this concern is broadly applicable to all high-dose folate supplementation
- GI effects (mild nausea, bloating) are uncommon at supplemental doses
- In cancer treatment at high pharmacological doses, leucovorin can cause GI side effects, rash, and fever — managed by the oncology team
Drug and nutrient interactions
- Methotrexate: This is the primary clinical interaction — folinic acid (leucovorin) rescues normal tissues from MTX toxicity. Timing of leucovorin relative to MTX dose is critical in high-dose MTX protocols; do not take folinic acid simultaneously with HD-MTX without oncologist guidance as it may partially reduce anti-tumor efficacy if given too early.
- Anticonvulsants (phenytoin, carbamazepine, valproate): These drugs can reduce serum folate levels by accelerating metabolism. Supplemental folate (in any form) may in turn modestly reduce anticonvulsant efficacy — discuss with your neurologist.
- Vitamin B12: High-dose folate (any form) can mask B12 deficiency anemia; always ensure adequate B12 status
- Sulfasalazine: Inhibits folate absorption; supplemental folate may be needed in long-term users
- Trimethoprim and pyrimethamine: Weak DHFR inhibitors; folinic acid may reduce their antifolate efficacy if used concurrently — generally avoided
Check our free interaction checker for additional combinations.
Who might benefit — and when it's not the right choice
| Appropriate use of folinic acid / calcium folinate | Better served by a different folate form |
|---|---|
| People on methotrexate experiencing GI side effects or mucositis (under prescriber supervision) | General population seeking folate supplementation → use folic acid or 5-MTHF |
| High-dose MTX chemotherapy rescue (leucovorin rescue — medical protocol only) | Pregnant women for NTD prevention → use folic acid 400–800 mcg (proven in RCTs) |
| People with severe MTHFR deficiency who cannot tolerate either folic acid or 5-MTHF well | MTHFR C677T variant seeking methylation support → 5-MTHF (methylfolate) bypasses MTHFR more completely |
| Individuals with documented DHFR impairment or confirmed poor folic acid conversion | People seeking general B-vitamin supplementation → use an active B complex with 5-MTHF |
Frequently asked questions
What is the difference between folinic acid and folic acid?
Folic acid is an oxidized synthetic form of folate that requires two DHFR-dependent reduction steps before entering active metabolism. Folinic acid (5-formyl-THF) is already in the tetrahydro (reduced) form and enters the folate cycle without DHFR. This distinction is critical when DHFR is inhibited by methotrexate — folic acid cannot rescue the block, but folinic acid can. For routine supplementation in people without DHFR issues, folic acid works for most people.
What is the difference between folinic acid and methylfolate (5-MTHF)?
Both bypass DHFR. The key difference is that folinic acid (5-formyl-THF) still requires MTHFR for the final conversion to 5-MTHF before methyl groups can be donated. Methylfolate (5-MTHF) bypasses MTHFR as well — it is the end-product that directly participates in the methionine synthase reaction. For MTHFR variant support, methylfolate (5-MTHF) is more directly effective. Folinic acid is specifically useful when DHFR is the rate-limiting step.
Is folinic acid (leucovorin) available as a supplement?
Yes. Calcium folinate is available as a dietary supplement, typically in capsule or tablet form at doses of 200–800 mcg. Higher doses (5+ mg) may require a prescription in some jurisdictions where leucovorin is regulated as a pharmaceutical. The supplement-dose forms are used for MTHFR support and MTX side effect reduction; the high-dose pharmaceutical forms are strictly medical use.
Should I take folinic acid if I have an MTHFR mutation?
It depends on the clinical context. For most people with MTHFR C677T or A1298C variants seeking methylation support, methylfolate (5-MTHF) is more directly effective because it bypasses MTHFR entirely. Folinic acid can be a useful alternative or addition for people who cannot tolerate methylfolate well (some experience anxiety or irritability with high-dose 5-MTHF), but it still requires a functioning MTHFR enzyme to reach its final active form. Discuss with a practitioner familiar with one-carbon metabolism.
Does folinic acid interact with methotrexate used for rheumatoid arthritis?
Yes, beneficially in this context. Taking folinic acid (typically 5 mg, 12–24 hours after the MTX dose) reduces MTX-related GI side effects, mouth sores, and fatigue without substantially reducing MTX's anti-inflammatory efficacy, as demonstrated in multiple RCTs and the Cochrane review. Folic acid (1–5 mg/day daily) is more commonly used for this purpose and is first-line, but folinic acid is an effective alternative for those with breakthrough side effects on folic acid.
Related ingredients and articles
Active B Complex
Contains 5-MTHF (methylfolate) alongside all 8 B vitamins in coenzymated forms.
Methylcobalamin (Methyl B12)
Essential cofactor alongside active folate in the methionine synthase / methylation cycle.
Methylated Multivitamin
Full-spectrum methylated multi providing 5-MTHF, methylcobalamin, and active B6.
Adenosylcobalamin (Adenosyl B12)
The mitochondrial B12 coenzyme — pairs with active folate forms for complete one-carbon support.
Disclaimer: This information is for educational purposes only and should not replace medical advice. Always consult a qualified healthcare provider before starting any supplement, especially if you have a medical condition, are pregnant, or take prescription medications. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.